Prothrombin complex concentrates utility for warfarin-associated hemorrhage.

Area of Science:

• Emergency Medicine
• Hematology
• Pharmacology

Background:

• Warfarin is a common anticoagulant, and its reversal is critical in life-threatening bleeding events.
• Prothrombin Complex Concentrate (PCC) is the primary therapeutic option for warfarin reversal.
• Four-factor PCC is increasingly utilized in emergency departments.

Purpose of the Study:

• To evaluate the efficacy and safety of 4-factor PCC in rapidly normalizing International Normalized Ratio (INR) values.
• To assess the use of 4-factor PCC for warfarin reversal in patients experiencing life-threatening bleeding in the Emergency Department.

Main Methods:

• Retrospective cohort study conducted in a tertiary care university emergency department.
• Included patients on warfarin with active bleeding and INR ≥1.5 who received 4-factor PCC.
• Analyzed INR normalization, transfusion requirements, and adverse events.

Main Results:

• 75 patients were included; median age was 68 years, 45.3% male.
• All patients who received 4-factor PCC achieved normalized INR levels.
• No thrombotic complications or adverse drug reactions were observed; 21% received RBC transfusions.

Conclusions:

• Four-factor PCC is effective in rapidly reversing the anticoagulant effects of warfarin.
• The study demonstrates the safety of 4-factor PCC administration in this patient population.
• 4-factor PCC is a viable and safe therapeutic option for managing life-threatening bleeding in warfarinized patients.